Organoids
1. Introduction to organoids-on-a-chip
Organoid-on-a-chip, which combines the two cutting-edge technologies of "organoid" + "organ-on-a-chip" in the field of life science and engineering, has been widely used in the fields of new drug research and development, disease modeling and personalized precision medicine.
Micro-pit array chips, micro-pillar array chips
Second, the direction of organoid application
Modeling, culture, and amplification of organoid diseases
Organoid-stromal cell co-culture
Multicellular co-culture
Stem cell exosome research
Drug Screening and Toxicology Studies
3. Advantages of tumor organoids
Disadvantages of traditional methods: multi-step operation; high human and economic costs; Embryoid bodies are easily fused
Advantages of tumor organoid-on-a-chip: simple operation, cost reduction, high throughput, microfluidics, standardization, and automation
4. Detection and analysis of drug sensitivity of tumor organoids-on-a-chip
1. Meaning
Tumor organoid drug susceptibility detection technology refers to the application of a variety of drug regimens to patient-derived tumor organoids for drug efficacy evaluation, so as to screen out the best drug regimen for the treatment of tumors and improve the treatment effect.
2. Detection significance
(1) Tumor tissues of patients are obtained intraoperatively, and tumor organoid models are established in vitro. Chemotherapy drugs and targeted drugs, drug concentration and timing are organically combined to quickly screen the best tumor treatment recommendations.
(2) Screening of tumor organoid chip drug susceptibility can provide clinicians with more information
Effective medication regimen to give personalized treatment to cancer patients.
(3) Accelerate the process of personalized medicine, reduce medical resources, and reduce the burden on patients' families.
3. Scope of application
(1) Patients who are resistant to chemotherapy drugs and targeted drugs should assist in formulating follow-up treatment plans.
(2) Preoperative neoadjuvant, postoperative treatment, and inoperable tumor patients should be assisted in formulating individualized medication plans.
(3) For first- and second-line drug-resistant cancer patients, screening cross-cancer clinical drug regimens.
(4) For patients with positive gene testing, gene editing technology was used for in vitro targeted verification.
(5) Patients with negative genetic testing will be screened for the optimal chemotherapy regimen.
(6) Patients with multi-gene and multi-target mutations can assist in formulating appropriate targeted treatment regimens.
(7) Other patients recommended by clinicians for tumor drug susceptibility testing will be assisted in precision treatment.